Procept CEO Buys 23,900 Shares at $20.85 After 48% Slump

For hospital and ambulatory surgery center executives tracking surgical robotics, Procept BioRobotics' AquaBeam system sits at a critical juncture: revenue reached $337.3 million over the trailing twelve months, yet the San Jose-based company remains unprofitable. CEO Larry Wood's August 7 purchase of 23,900 shares at $20.85—about 2.2% above that day's close—puts $498,315 of his own capital behind the BPH treatment platform. That insider signal matters for urology service line leaders deciding whether Aquablation therapy warrants deeper investment amid a 48% stock slide.

On August 7, 2026, Procept BioRobotics Corporation (PRCT) President and CEO Larry L. Wood acquired 23,900 shares of common stock through The Larry Wood Trust at a weighted average price of $20.85 per share, a transaction valued at approximately $498,315. The purchase was disclosed in an SEC Form 4 filing and analyzed by The Motley Fool on August 18, 2026. The move came as the stock closed at $20.41 on the transaction date, leaving shares down roughly 48% on a one-year basis.

“

CEO Larry Wood's August 7 purchase of 23,900 shares at $20.85—about 2.2% above that day's close—puts $498,315 of his own capital behind the BPH treatment platform.

The transaction is notable less for its absolute size than for what it reveals about insider sentiment and ownership structure. Before the purchase, Wood already held about 314,000 shares directly; the new indirect position raises his total beneficial ownership to 338,103 shares. Yet Procept's aggregate insider ownership remains just 0.59% of the $1.2 billion company, which means this transaction, while positive, is a relatively small incremental alignment signal in the context of the broader shareholder base. The fact that the purchase was made through a trust is also relevant: trust-based acquisitions can reflect estate planning or tax considerations as much as a pure market call, and investors should avoid overinterpreting a single Form 4 as a definitive bottom signal.

For context, Procept BioRobotics develops and commercializes the AquaBeam Robotic System, a minimally invasive surgical robot used for Aquablation therapy to treat benign prostatic hyperplasia (BPH). The company generates revenue from system sales, consumable supplies, and service agreements to hospitals, urology departments, and ambulatory surgical centers. The financial snapshot is mixed: trailing twelve-month revenue reached $337.3 million, but the company still reported a net loss of $109.8 million over the same period. That combination of growing revenue and ongoing losses is common among surgical robotics and medical device companies investing heavily in commercialization, but it also explains why the stock has been vulnerable to the 48% decline.

The insider purchase mechanics carry a modest but real informational signal. Wood paid $20.85 per share, about 2.2% above the $20.41 close on August 7, indicating a willingness to buy at a slight premium rather than waiting for a lower fill. In the insider-following framework, officers typically sell for diversification or liquidity reasons, while buys are generally considered more informative because they represent a discretionary use of personal capital. However, that signal is tempered by the trust structure, the modest percentage of insider ownership, and the fact that executives can be wrong about timing, particularly in a volatile, high-multiple medical device sector.